BIOX
Overvalued by 328.8% based on the discounted cash flow analysis.
Market cap | $295.37 Million |
---|---|
Enterprise Value | $560.57 Million |
Dividend Yield | $0 (0%) |
Earnings per Share | $0.05 |
Beta | 0.4 |
Outstanding Shares | 62,822,158 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 115.16 |
---|---|
PEG | 582.13 |
Price to Sales | 0.67 |
Price to Book Ratio | 0.94 |
Enterprise Value to Revenue | 1.27 |
Enterprise Value to EBIT | 13.07 |
Enterprise Value to Net Income | 223 |
Total Debt to Enterprise | 0.53 |
Debt to Equity | 0.95 |
No data
No data